Arvinas/Pfizer report vepdegestrant+abemaciclib Phase 1b: 62.5% CBR, 26.7% ORR in post-CDK4/6 breast cancer

ARVINAS, INC.

62.5% clinical benefit rate (10/16) and 26.7% ORR (4/15) in ER+/HER2- advanced breast cancer patients all previously treated with CDK4/6 inhibitor.
No significant drug-drug interaction between vepdegestrant (200mg QD) and abemaciclib (150mg BID); no grade 4/5 TEAEs.
Recommended Phase 2 dose confirmed: vepdegestrant 200mg QD + abemaciclib 150mg BID; Phase 2 portion ongoing.
Data cut-off Aug 30, 2024; presented Dec 12, 2024 at SABCS; 5 of 16 patients remain on treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.